Other

Genematrix Inc.

Cheiljedang Corp.

Sun Pyo Hong

Soo Ok Kim

Hyun Su Kim

Suk Joon Kim

Wang Don Yoo

Jin Woo Kim

Jae Il Kim

Jung Hwan Choi

Jae Yeong Lee

Sang Seok Lee

Kenneth H Eckels

Hwang Joon Lee

Yong Cheol Shin

Man Hee Kim

Young Gi Kim

Yang Je Cho

Je Hak Kim

Doria R Dubois

Bruce L Innis

Yun Sung Lee

Sun Young Hwang

Dong Eok Lee

Ki Ho Chung

Sung Hee Lee

Soo-Ok Kim

Jeong Woo Kim

Dal Hyun Kim

Joseph R Puniak

Ashok K Srivastava

Seong Soo Hong

Leonard N Binn

Bong I Kim

Mun K Kim

Young K An

Hyun Jae Chung

Sun Young Jeong

Nam C Kang

Wan Je Park

Ree An Yoo

Nam Joong Lee

Kap Soo Noh

Woo Jae Cho

Suk Hoon Ha

Sun Ok Jang

Sang Hyun Lee

Seung Min Yang

Sang Bum Moon

Ae Ri Cho

Yong Ju Chung

Soo-Kyung Shin

Ji Young Shin

Joo Hyoung Lee

Wangdon Yoo

Sukjoon Kim

Sun Min Park

The present invention relates to a chimeric recombinant protein having a therapeutic effect on cervical cancer by fusing genetic modified E6 and E7, which are carcinogenesis-inducing proteins of human papillomavirus high-risk group type 16, with a fusion protein for increasing immunogenicity, the HPV type 16 E6, E7 chimeric recombinant protein fused with the flagellin fusion protein of the present invention showed the lowest tumor cell volume, and the immune response of specific T cells according to the recombinant antigen was significantly confirmed, and when the prophylactic effect was measured, it was confirmed that the volume of tumor cells was low and the antibody titer was increased, therefore human papillomavirus recombinant antigen of the present invention shows tumor treatment and prophylaxis and can be applied as a therapeutic/prophylactic vaccine composition.

Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein

The present invention relates to a method and a composition for detecting a target nucleic acid sequence using a cleaved complementary tag fragment. Specifically, the present invention relates to a method for linking a complementary tag sequence to a PCR primer so that a tagging can be produced by a restriction enzyme during a PCR reaction, diversifying the complementary tag sequence to be linked to each primer by utilizing factors such as length and nucleic acid combination, etc., and distinguishing the target sequence using the same. According to the present invention, a cleaved complementary tag fragment (CCTF) under stringent conditions is a complementary sequence to any sequence at the 5' end linked to the primer and cannot be formed unless a PCR reaction and a restriction enzyme reaction occur, and the cleaved single strand is formed only when hybridization to the target sequence occurs and a primer extension product complementary to the target sequence is formed, so as to have a higher degree of accuracy secured by reading the cleaved single strand. In addition, the CCTF can be used to identify a plurality of target nucleic acid sequences by selecting various analytical techniques and analysis equipment according to a user's intention. For example, a result can be confirmed rapidly and accurately in genetic testing, identification of organisms in a sample, diagnosis of microbial or viral infection, etc.

Method for detecting target nucleic acid sequence using cleaved complementary tag fragment and a composition therefor

An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.

Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine

The present invention relates to a vaccine prepared from an attenuated Pseudomonas aeruginosa strains which are obtained by isolating Pseudomonas aeruginosa in a pure state according to the Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035) strains. In addition, the present invention relates to a process for preparing the vaccine for immunization against Pseudomonas aeruginosa infection which contains cell wall proteins having molecular weights ranging from 10,000 to 100,000. The cell wall protein component of the attenuated strain is non-pathogenic and safe, and exhibits excellent antibody formation capacity and is useful for preparation of a vaccine and therapeutic agent. The cell wall proteins exhibit an excellent cross-protective efficacy for various Pseudomonas aeruginosa strains and a superior antibody inducing property.

Process for preparing a vaccine against pseudomonas aeruginosa using

A method of fingerprint verification includes determining a direction difference between a direction pattern of an input fingerprint and a direction pattern of a registered fingerprint and comparing the determined direction difference with predetermined upper and lower threshold values. The input and registered fingerprints are considered the same if the direction difference is lower than the lower threshold value, and the input and registered fingerprints are considered to be different if the direction difference is higher than the upper threshold value. If the direction different is between the upper and lower threshold values, minutiae of the input and registered fingerprints are extracted for verifying the input fingerprint. The extracting includes preprocessing of the input fingerprint image, uniboundary extraction of the input fingerprint minutiae, and restoration to eliminate pseudo-minutiae.

Method of fingerprint verification

Growing community of inventors

Seoul, South Korea

Sun Pyo Hong